4.8 Review

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

Journal

NATURE REVIEWS DRUG DISCOVERY
Volume 15, Issue 1, Pages 51-69

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nrd.2015.9

Keywords

-

Funding

  1. European Marie Curie Initial Training Network [NR-NET 606806]
  2. Italian Association for Cancer Research (AIRC) [IG 14732]
  3. Italian Ministry of University and Education [IDEAS RBID08C9N7, 2010FHH32M-002]
  4. Italian Ministry of Health [GR-2010-2314703]
  5. Intercept Pharmaceuticals (San Diego CA)
  6. NGM BioPharmaceuticals (San Francisco CA)
  7. University of Bari Aldo Moro [IDEA GRBA0802SJ-2008]

Ask authors/readers for more resources

The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism, modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogues and mimetics are now being investigated. Here, we discuss current knowledge of the complex biology of the endocrine FGFs and assess how this may be harnessed therapeutically.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available